ProCE Banner Activity

An Expert’s Guide to ASCO 2020: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Experts highlight key studies being presented at the upcoming 2020 ASCO virtual meeting. The CCO ASCO Virtual Conference Coverage program will have the information you need to understand and integrate the latest oncology data into your practice.

Released: May 27, 2020

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Axel Grothey

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Manish A. Shah

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees from Curis, Forma, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm Therapeutics, Kite, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roches, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem and has personal ownership in Johnson & Johnson.

Axel Grothey, MD

Professor, Oncology
Mayo Clinic
Rochester, Minnesota

Axel Grothey, MD, has disclosed that he has received consulting fees (paid to his institution) from Array/Pfizer, Bayer, Boston Biomedicals, Bristol-Myers Squibb, Genentech, and Roche.

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Bayer, Daiichi-Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, OBI Pharma, Pfizer, Pieris, Puma, Radius, Sanofi, and Seattle Genetics and editorial support from Pfizer and Roche.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support paid to the institution from AbbVie, Amgen, Bristol-Myers Squibb, CARsgen, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Takeda, Tenebio and consulting fees (paid to his institution) from AbbVie, Amgen, Celgene, Genentech, Janssen, Molecular Partners, and Takeda and (with personal payment) from Cellectar, GeneCentrix, and Oncopeptides.

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received funds for research support from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech/Roche, Lilly, Lycera, Merck/MSD, Merus, Molecular Partners, Pfizer, Rain Therapeutics, RAPT, Spectrum, and Turning Point; consulting fees from AstraZeneca, Bristol-Myers Squibb, Catalyst, Celgene, G1 Therapeutics, Genentech/Roche, Guardant, Janssen, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, and Takeda; and other financial or material support from Boehringer Ingelheim.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, and Urogen; has received funds for research support from Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Endocyte, Genentech, Innocrin, Lilly, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi, and Seattle Genetics; and has ownership interests in Bellicum and Tyme.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received consulting fees from AstraZeneca, Genentech, Incyte, Lilly, and Medtronic and funds for research support from AstraZeneca, Novartis, Spectrum, Takeda, and Tesaro.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from Astellas, Bristol-Myers Squibb, Genentech, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Flatiron, Genentech, Janssen, Merck, Pfizer, and Seattle Genetics.

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, MacroGenics, Orsenix, and Xencor and consulting fees from AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Jazz, Novartis, Orsenix, and Xencor.

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Manish A. Shah, MD, has disclosed that he has received funds for research support from Astellas, Bristol-Myers Squibb, and Merck.